TauRx Announces Completion of Phase 3 Study Enrolment for the First Tau-based Disease Modifying Treatment for Alzheimer's Disease

Aberdeen, Scotland and Singapore, Singapore--(Newsfile Corp. - January 11, 2021) - TauRx Pharmaceuticals Ltd today announced it has completed patient enrolment of the LUCIDITY study (NCT03446001) ahead of schedule, despite delays due to the COVID-19 pandemic. TauRx is pleased to be presenting its latest trial results at Biotech Showcase 2021 during the J.P. Morgan 39th Annual Healthcare Conference 2021. LUCIDITY is the only late-stage study targeting the tau pathology of Alzheimer's disease. It aims to confirm hydromethylthionine as the first tau-based disease modifying treatment for Mild Cognitive Impairment and Mild-Moderate AD.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • TauRx Pharmaceuticals Ltd today announced it has completed patient enrolment of the LUCIDITY study (NCT03446001) ahead of schedule, despite delays due to the COVID-19 pandemic.
  • TauRx is pleased to be presenting its latest trial results at Biotech Showcase 2021 during the J.P. Morgan 39th Annual Healthcare Conference 2021.
  • If the efficacy of hydromethylthionine is confirmed, it will open up a completely new treatment direction for a devastating disease which has so far defied all efforts to bring it under control.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7294/71720_figure1_550.jpg

Click image above to view full announcement.

Contacts:

TauRx Media
r.andersen@taurx.com

Source: TauRx

Back to news